Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neovascular glaucoma prevention by intravitreal aflibercept in proton therapy-treated large choroidal melanoma
2024-513746-11-00Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Oct 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in neovascular glaucoma (NVG), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Occurrence of neovascular glaucoma. Started Oct 2024; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on 2024-513746-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513746-11-00.